Avid Bioservices Inc (CDMO)

[entdoc]

wwtmm, do you have a reference to the article on ipilimumab use with irradiation therapy? I am curious whether it is in clinical trials with irradiation therapy, or if the info. is from lower animals (as with Bavi + irrad.). The MAB, as correctly pointed out here by others, has some problems which are tolerable in light of the clinical trial indications for its use (metastatic malignant melanoma), but it "umblocks" the immune system by a pathway different than bavituximab. There is a good recent article out of Duke (Prostate, 2012 Feb;72(3):338-49.doi:10.1002/pros.2145 Emerging treatment options for patients with castration-resistant prostate cancer by George D, Moul JW)in which Bavi is not mentioned, concluding, "Various combinations of these (MABs) agents could theoretically be used to treat future patients...by targeting multiple signaling pathways as well as aspects of the tumor microenvironment". Additional research will be needed to understand how to best use these agents and individualize care to optimize...patient outcomes".